CHURCHILL MANAGEMENT Corp Makes New $8.28 Million Investment in Pfizer Inc. (NYSE:PFE)

CHURCHILL MANAGEMENT Corp acquired a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 326,865 shares of the biopharmaceutical company's stock, valued at approximately $8,283,000.

Several other large investors have also recently added to or reduced their stakes in PFE. Rialto Wealth Management LLC bought a new stake in Pfizer during the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $27,000. Gould Capital LLC raised its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter worth approximately $30,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.3%

Shares of Pfizer stock traded up $0.32 on Wednesday, hitting $25.36. 14,983,180 shares of the company traded hands, compared to its average volume of 41,418,262. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market cap of $144.15 billion, a PE ratio of 18.37, a PEG ratio of 0.88 and a beta of 0.58. The company has a 50-day moving average price of $23.56 and a 200 day moving average price of $24.83.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the company posted $0.82 earnings per share. The business's quarterly revenue was down 7.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.78%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is presently 124.64%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.